SCHEMBL2919962

SCHEMBL2919962

COc1ccc(-n2nc(C(=O)N3CCCCN3C(N)=O)cc2-c2ccccn2)cn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 2/20 0.35
PIK3CA P42336 2/20 0.35
PIK3CD O00329 1/20 0.35
PIK3R2 O00459 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
PIK3R5 Q8WYR1 1/20 0.35
PIK3R3 Q92569 1/20 0.35
NTRK1 P04629 2/20 0.35
KLK3 P07288 1/20 0.35
PTGS2 P35354 3/20 0.35
RPA1 P27694 1/20 0.35
ADORA2A P29274 1/20 0.35
MGLL Q99685 3/20 0.35
CHRNB2 P17787 1/20 0.34
CHRNA4 P43681 1/20 0.34
MALT1 Q9UDY8 1/20 0.34
PTGS1 P23219 1/20 0.34
ABL1 P00519 1/20 0.34
BCR P11274 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2919524 0.92 PIK3CD (0.36) CFTRPIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL2912043 0.88 PIK3CD (0.34) CFTRPIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL13637539 0.87 MALT1 (0.45) CFTRPIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL5269112 0.86 CFTR (0.38) CFTRPIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL5267011 0.86 PIK3CD (0.34) CFTRPIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL5270461 0.85 PTGS2 (0.35) CFTRPIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL2910449 0.84 CHRNB2 (0.39) PIK3CAPIK3CDPIK3R2PIK3CBPIK3CG
SCHEMBL2920732 0.84 SCD5 (0.39) PIK3CDNTRK1MGLLHPGD
SCHEMBL2920771 0.83 PIK3CD (0.36) CFTRPIK3CAPIK3CDPIK3R2PIK3CB
SCHEMBL5270340 0.83 CHRNB2 (0.41) PIK3CAPIK3CDPIK3R2PIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 US disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 CFTR 1992/4885PIK3CA 2762/4885PIK3CD 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.